Sophiris Bio (SPHS) has been under a strong bear grip, hence the stock is down -48.35% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 7.94% in the past 1 week. The stock has risen by 8.52% in the past week indicating that the buyers are active at lower levels, but the stock is down -49.4% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 16.58% and the 50-Day Moving Average is 27.03%.The 200 Day SMA reached 32.67% Sophiris Bio, Inc. is up 45.77% in the last 3-month period. Year-to-Date the stock performance stands at 64.61%.
Sophiris Bio (SPHS) has been rated by 4 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $8 and the lowest price target forecast is $6. The average forecast of all the analysts is $6.75 and the expected standard deviation is $0.96.
For the current week, the company shares have a recommendation consensus of Buy. Sophiris Bio (NASDAQ:SPHS): stock was range-bound between the intraday low of $2.86 and the intraday high of $3.05 after having opened at $3.03 on Fridays session. The stock finally closed in the red at $3.03, a loss of -2.01%. The stock remained in the red for the whole trading day. The total traded volume was 1,357,793 shares. The stock failed to cross $3.05 in Fridays trading. The stocks closing price on Thursday was $2.93.
Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.